

Table S2 Cost calculation of drug treated CFPS reactions

Drug (TargetMol ^a)	Cost (USD/mg)	Cost CFPS (USD/ L reaction)	% Cost (CrP/CrK)	% Cost (glucose)	nLuc Yield (µg/mL)	Cost efficiency (µg nLuc/USD)	Fold increase in cost efficiency ^b	Fold increase in cost efficiency ^c
<i>Bosutinib</i>	0.88	46.68	1.56%	4.67%	18.1	17.29	4.80	2.51
<i>Cerdulatinib</i>	2.16	96.23	3.21%	9.62%	12.9	11.77	3.27	1.71
<i>Nafarelin Acetate</i>	2.16	302.52	10.08%	30.25%	25.3	19.42	5.40	2.82
<i>Dasatinib</i>	0.20	58.56	1.95%	5.86%	11.5	10.86	3.02	1.57
<i>Neratinib</i>	0.66	14.71	0.49%	1.47%	<i>N.A.</i>	<i>N.A.</i>	<i>N.A.</i>	<i>N.A.</i>
<i>Afatinib</i>	0.63	30.61	1.02%	3.06%	<i>N.A.</i>	<i>N.A.</i>	<i>N.A.</i>	<i>N.A.</i>
<i>Polymyxin B</i>	0.03	4.16	0.14%	0.42%	<i>N.A.</i>	<i>N.A.</i>	<i>N.A.</i>	<i>N.A.</i>
<i>Nafarelin + Cerdulatinib</i>	4.32	398.75	13.29%	39.87%	49.7	35.53	9.87	5.15
<i>Control (current)</i>	0.00	0.00	<i>N.A.</i>	<i>N.A.</i>	6.9	6.90	1.92	1.00
<i>Control (reported)</i>	0.00	0.00	<i>N.A.</i>	<i>N.A.</i>	3.6	3.60	1.00	0.52

^a Cost of drugs obtained from TargetMol website

^b Fold increase in cost efficiency is calculated with respect to reported cost efficiency using optimised glucose system¹

^c Fold increase in cost efficiency is calculated with respect to cost efficiency of untreated control in the current study

Reference:

1. M. J. Anderson, J. C. Stark, C. E. Hodgman and M. C. Jewett, *FEBS Lett*, 2015, **589**, 1723-1727.